Monthly injections with HIV therapies from GlaxoSmithKline Plc (GSK) and Johnson & Johnson (JNJ:US) sustained levels of the drugs in blood that should control the virus, according to a study that suggests the shots may one day provide a safer, more convenient treatment option to daily pills.
In a trial among 40 HIV-negative volunteers of Glaxo’s GSK744 and J&J’s TMC278, monthly injections sustained drug levels above a predetermined threshold considered necessary to control HIV, during the trial and for four months after the last shot, according to results presented at the International AIDS Society’s meeting in Kuala Lumpur today.